Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07739199 PD-1/VEGF Trispecific Antibody(Harbour) Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07739199 PD-1/VEGF Trispecific Antibody(Harbour) Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739199 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Read →
NCT07739186 PD-1/VEGF Trispecific Antibody(Harbour) Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07739186 PD-1/VEGF Trispecific Antibody(Harbour) Metastatic Non-Squamous Non-Small Cell Lung Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07739186 clinical trial report covering PD-1/VEGF Trispecific Antibody(Harbour), Phase 2/3, endpoints, sponsor, geography, readout timing and developmen
Read →
NCT07742553 Finasteride Hypogonadism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07742553 Finasteride Hypogonadism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07742553 clinical trial report covering Finasteride, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07725484 Lipoic acid Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07725484 Lipoic acid Coronary Artery Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07725484 clinical trial report covering Lipoic acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07723911 Blinatumomab CD19-positive B-cell acute lymphoblastic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07723911 Blinatumomab CD19-positive B-cell acute lymphoblastic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07723911 clinical trial report covering Blinatumomab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600128985 Albumin-Bound Paclitaxel Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600128985 Albumin-Bound Paclitaxel Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
ChiCTR2600128985 clinical trial report covering Albumin-Bound Paclitaxel, Phase 3, endpoints, sponsor, geography, readout timing and development white spac
Read →
NCT07735117 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07735117 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07735117 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07733765 Ritlecitinib Tosilate Alopecia Areata Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07733765 Ritlecitinib Tosilate Alopecia Areata Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733765 clinical trial report covering Ritlecitinib Tosilate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07734311 Ecnoglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07734311 Ecnoglutide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734311 clinical trial report covering Ecnoglutide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07733947 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07733947 Resveratrol/Curcumin Subcutaneous fat disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733947 clinical trial report covering Resveratrol/Curcumin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07734844 Tabirafusp alfa tedromer Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07734844 Tabirafusp alfa tedromer Diabetic macular oedema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734844 clinical trial report covering Tabirafusp alfa tedromer, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07734155 Levonorgestrel Contraception Behavior Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07734155 Levonorgestrel Contraception Behavior Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734155 clinical trial report covering Levonorgestrel, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →